Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and nivolumab maintenance after first-line platinum response in advanced ovarian cancer
2017-004557-17Phase 3Unknown
- Sponsor
- Clovis Oncology
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rucaparib and nivolumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Clovis Oncology. Primary endpoint: Investigator-determined progression-free survival. Status: unknown.
02
Drugs
rucaparibnivolumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-004557-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004557-17.